Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Patent Office (EPO) has issued a patent (number 1802775) on methods of treating heart failure patients with Gencaro (bucindolol hydrochloride) based on genetic targeting to ARCA biopharma.
Subscribe to our email newsletter
The patent entitled ‘Methods for Treatment with Bucindolol Based on Genetic Targeting,’ provides protection for this approach to treat patients with heart failure in France, Germany, Netherlands, Switzerland/Liechtenstein, Great Britain, Ireland, Luxembourg, Monaco, Spain, Italy and Sweden.
Gencaro is an oral tablet formulation, dosed twice daily. Gencaro is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor.
ARCA biopharma president and CEO Michael Bristow said that they are obviously pleased with the European Patent Office’s issuance of this patent, which they believe will extend their pharmacogenetic intellectual property protection around bucindolol and, if approved for marketing, provide Gencaro market exclusivity in the designated countries into 2025.